- Home
- ERAS vs BOE Comparison
ERAS vs BOE Comparison
Compare ERAS & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- BOE
- Stock Information
- Founded
- ERAS 2018
- BOE 2005
- Country
- ERAS United States
- BOE United States
- Employees
- ERAS N/A
- BOE N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- BOE Trusts Except Educational Religious and Charitable
- Sector
- ERAS Health Care
- BOE Finance
- Exchange
- ERAS Nasdaq
- BOE Nasdaq
- Market Cap
- ERAS 723.8M
- BOE 688.5M
- IPO Year
- ERAS 2021
- BOE N/A
- Fundamental
- Price
- ERAS $1.90
- BOE $11.21
- Analyst Decision
- ERAS Strong Buy
- BOE
- Analyst Count
- ERAS 5
- BOE 0
- Target Price
- ERAS $5.70
- BOE N/A
- AVG Volume (30 Days)
- ERAS 1.5M
- BOE 166.1K
- Earning Date
- ERAS 11-12-2024
- BOE 01-01-0001
- Dividend Yield
- ERAS N/A
- BOE 7.30%
- EPS Growth
- ERAS N/A
- BOE N/A
- EPS
- ERAS N/A
- BOE N/A
- Revenue
- ERAS N/A
- BOE N/A
- Revenue This Year
- ERAS N/A
- BOE N/A
- Revenue Next Year
- ERAS N/A
- BOE N/A
- P/E Ratio
- ERAS N/A
- BOE N/A
- Revenue Growth
- ERAS N/A
- BOE N/A
- 52 Week Low
- ERAS $1.64
- BOE $8.80
- 52 Week High
- ERAS $3.45
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- ERAS 29.70
- BOE 58.78
- Support Level
- ERAS $1.77
- BOE $10.70
- Resistance Level
- ERAS $2.84
- BOE $11.08
- Average True Range (ATR)
- ERAS 0.18
- BOE 0.12
- MACD
- ERAS -0.07
- BOE 0.05
- Stochastic Oscillator
- ERAS 12.15
- BOE 83.93
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.